Skip to content
๐Ÿฉบ Medicare & health costs

Do Medicare drug price negotiation and the $35 insulin cap lower what I pay at the pharmacy?

Asked by BudgetSeniors team ยท 3 months ago

Say you’re on Original Medicare with a stand-alone Part D plan, and you take Eliquis for a blood clot risk, Jardiance for diabetes and a long-acting insulin. You keep reading that Medicare now negotiates drug prices and that insulin is capped at $35 a month, yet your pharmacy receipts barely changed. Some of your medicines are on the negotiated list, some aren’t, and your plan charges a flat copay on one drug but a percentage on another. Which of these changes should actually show up in your out-of-pocket costs, and which ones only help Medicare and the plan?

See alsoDoes the Medicare Prescription Payment Plan lower my drug bill or just spread it out?

1 reply

  1. BudgetSeniors team Team 3 months ago

    Whether you save money depends on one thing before anything else: how your Part D plan charges you for each drug, a flat copayment or a percentage. If a drug on your list is one of the ones with a negotiated price, and your plan charges coinsurance, your share can drop. If your plan charges a flat copay, the savings mostly stay with the plan. Insulin is different, because it has its own hard limit that doesn't depend on any of that. This is general information, not medical or insurance advice, so check your own plan's drug list before you change anything.

    Here's how the pieces fit together. There are three separate things happening, and people often blend them into one.

    Medicare drug price negotiation: what it is and which drugs

    The Inflation Reduction Act lets Medicare negotiate prices for a limited list of high-spending drugs. Medicare calls the result a maximum fair price. The first round covered 10 Part D drugs, and the prices took effect on January 1, 2026. KFF lists them as Eliquis and Xarelto for blood clots, Jardiance, Farxiga, Januvia and Fiasp/NovoLog for diabetes, Entresto for heart failure, Stelara and Enbrel for psoriasis, arthritis and Crohn's disease, and Imbruvica for blood cancers.

    Advertisement

    The second round has 15 more Part D drugs, with negotiated prices starting January 1, 2027. CMS's own list includes Ozempic, Rybelsus and Wegovy, Trelegy Ellipta, Breo Ellipta, Xtandi, Ibrance, Calquence, Pomalyst, Janumet, Tradjenta, Otezla, Linzess, Ofev, Vraylar and Xifaxan. A third round of 15 drugs, which can include Part B drugs, was picked in January 2026 and the negotiated prices start in 2028.

    CMS estimates the first-round prices will save people with Medicare about $1.5 billion in out-of-pocket costs in 2026 and the second round about $685 million in 2027. Those are program-wide estimates. They tell you the direction, not what you'll pay.

    Why your pharmacy bill might not move

    This is the catch. A negotiated price lowers what Medicare and your plan pay. It lowers your bill only if your cost is tied to the price. KFF puts it this way: if you pay coinsurance for a drug, you could see savings from a negotiated price that is lower than your plan's price, but if your plan uses a flat copayment, you won't necessarily see a difference.

    Say your plan's price for a 30-day supply of a drug is $400 and you pay 25% coinsurance, which is $100. If the negotiated price is $274, the same 25% comes to $68.50, so you'd save $31.50 a month, or $378 over a year. Now say your plan charges a flat $47 copay for that drug. Your cost may stay $47 at the counter. The savings would go to the plan, though over time that can show up in premiums or plan design.

    For reference, KFF reported that the negotiated price for semaglutide, sold as Ozempic and Wegovy, is $274 for a 30-day supply, and that a separate White House agreement announced a $245 Medicare price for the same drug. KFF noted it was unclear how the two prices will interact. If you take one of these, ask your plan which price it will use in 2027.

    The $35 insulin limit works differently

    Insulin has a flat limit set by Medicare, not by negotiation. Medicare.gov says the cost of a one-month supply of each Part B or Part D covered insulin product is no more than $35, and you don't pay a deductible for it. A three-month supply costs no more than $35 for each month, so generally $105 at most for each covered insulin product. The $35 applies to everyone who takes insulin, including people who get Extra Help.

    Advertisement

    Two details matter:

    • The limit is per insulin product, so if you use two different insulins, each can cost up to $35 a month.
    • Part B covers insulin only when it's used with an insulin pump that counts as durable medical equipment; pens and other injected insulin fall under Part D. If you have a Medigap policy that pays your Part B coinsurance, it should cover the $35 or less.

    Supplies are separate. Medicare.gov says that for insulin-related supplies like syringes, needles, alcohol swabs and gauze, you pay all costs under Part B unless you have Part D, so ask whether your Part D plan covers them.

    The bigger cap that protects everyone

    The other number to know is the Part D out-of-pocket limit. Medicare.gov says that after you pay 25% coinsurance in the initial coverage stage, once your spending on covered Part D drugs reaches $2,100 in 2026 ($2,400 in 2027), you pay nothing more for covered drugs for the rest of the year. No plan's deductible can be more than $615 in 2026 ($700 in 2027), and some plans have none.

    Put those together. Say you take two expensive brand drugs in 2026 and your plan has a $615 deductible. You'd pay the full price of your drugs until you hit $615, then 25% until your total hits $2,100. After that, $0. Negotiated prices can slow how fast you climb toward that ceiling if you pay coinsurance. But if your drugs are costly enough that you'd reach the cap anyway, a lower price changes when you hit it rather than how much you spend in the year. The cap is what keeps the year's total from growing.

    What to do before you assume anything

    Make a list of every medicine you take, with the strength and how many days each prescription covers. Then:

    • Check each one against the negotiated lists above. The ones with prices already in effect are the first-round drugs. The second-round prices don't start until January 1, 2027.
    • Look at your plan's drug list (the formulary) and see whether each drug is a flat copay or coinsurance. Your Evidence of Coverage spells this out.
    • If you take insulin, confirm the pharmacy is charging no more than $35 per product per month. If it charges more, ask the pharmacist to check the plan's insulin coverage, and call the plan.
    • During the fall open enrollment period, price your actual medicines in the Medicare Plan Finder. Plans change formularies and cost sharing every year, so last year's cheap plan can be this year's expensive one.

    If cost is already a struggle, two free supports exist that have nothing to do with negotiation. Extra Help can lower your Part D costs if your income and resources qualify, and your State Health Insurance Assistance Program offers one-on-one help with plan comparisons. Call 1-800-MEDICARE (1-800-633-4227) or the Eldercare Locator (1-800-677-1116) to find local counselors. Nobody should charge you a fee to compare plans or apply for Extra Help.

    One more thing to watch: news about drug prices moves fast. Prices announced in headlines are not always what your plan charges, and some scam callers use "new Medicare drug prices" as bait. If an unexpected caller asks for your Medicare number or pushes you to switch plans, hang up, don't pay anything, and report it to the FTC at ReportFraud.

    If your plan's own notice or drug list says something different from the figures here, go by the notice and call the plan to ask why.

    Key sources: Medicare.gov; CMS; KFF

Add your reply

Your email is never shown. Be kind โ€” someone may be worried about money. Never post account, Social Security or Medicare numbers.